Search

Kidney cancer’s genomic drivers revealed

Kidney cancer’s genomic drivers revealed

November 04, 2015
A massive search involving cancer researchers across the U.S. and Canada has revealed many of the altered genes and cell signaling pathways that drive a poorly understood form of kidney cancer, primary papillary renal cell carcinoma.

Immunovia, OHSU collaborating on early detection test for pancreatic cancer

October 04, 2015
Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

Annual Pacific NW Prostate Cancer Conference slated for Sept. 19

September 09, 2015
OHSU Knight Cancer Institute, in conjunction with University of Washington School of Medicine and University of British Columbia Cancer Agency Research Centre, is hosting the 15th annual NW Prostate Cancer Conference. The region’s ...

Collaborative Cancer Cloud launches

September 03, 2015
The following is an excerpt of the Aug. 19, 2015, Directline from the President’s Office. A little more than two years ago, OHSU and Intel joined forces to combine next-generation computing platforms with our unique capabilities in biomedical ...

Tuality Healthcare and OHSU sign letter of intent to affiliate

August 18, 2015
Tuality Healthcare and Oregon Health & Science University (OHSU) have signed a letter of intent (LOI) to pursue an affiliation that would integrate Tuality’s clinical enterprise with OHSU’s health care enterprise. If a final agreement is reached, Tuality’s clinical operations will be managed by OHSU, under the strategic direction of a recently announced management company called OHSU Partners.
See More Stories